These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8142155)

  • 1. Leuprolide and tamoxifen in the treatment of pancreatic cancer. A phase II study.
    Zaniboni A; Meriggi F; Arcangeli G; Alghisi A; Huscher C; Marini G
    Eur J Cancer; 1994; 30A(1):128. PubMed ID: 8142155
    [No Abstract]   [Full Text] [Related]  

  • 2. Tamoxifen or cyproterone acetate in combination with buserelin are ineffective in patients with pancreatic adenocarcinoma.
    Swarovsky B; Wolf M; Havemann K; Arnold R
    Oncology; 1993; 50(4):226-9. PubMed ID: 8497375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormone therapy of postoperative recurrent pancreatic carcinoma with octreotide and tamoxifen].
    Wenger FA; Zieren HU; Jacobi CA; Müller JM
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115():1348-50. PubMed ID: 9931878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer.
    Eckel F; Lersch C; Lippl F; Assmann G; Schulte-Frohlinde E
    J Exp Clin Cancer Res; 2000 Sep; 19(3):295-300. PubMed ID: 11144522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Concomitant arterial infusion chemotherapy with tamoxifen therapy for hepatic metastases from pancreatic adenocarcinoma--a preliminary report].
    Saito H; Takamura A; Sakurai Y; Horio K; Ohta T; Yamano M; Sawaguchi Y; Sato Y
    Gan To Kagaku Ryoho; 1993 Nov; 20(14):2177-82. PubMed ID: 8239683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. EORTC Gastrointestinal Group.
    Wils J; Bleiberg H; Buyse M; Wagener DT; Splinter T; Veenhof C; Herben M; Duez N
    Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1119-20. PubMed ID: 2759166
    [No Abstract]   [Full Text] [Related]  

  • 7. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas.
    Rosenberg L; Barkun AN; Denis MH; Pollak M
    Cancer; 1995 Jan; 75(1):23-8. PubMed ID: 7804972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: a pilot study.
    Louvet C; Beerblock K; de Gramont A; Varette C; Demuynck B; Bennamoun M; Cady J; Delfau S; Maisani JE; Krulik M
    Eur J Cancer; 1993; 29A(8):1217. PubMed ID: 8518038
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma.
    Crowson MC; Dorrell A; Rolfe EB; Fielding JW
    Eur J Surg Oncol; 1986 Dec; 12(4):335-6. PubMed ID: 3780986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma.
    Raymond E; de Gramont A; Louvet C; Tournigand C; Demuynck B; Beerblock K; Carola E; Krulik M
    Eur J Cancer; 1997 Apr; 33(4):696-7. PubMed ID: 9274458
    [No Abstract]   [Full Text] [Related]  

  • 11. Ifosfamide plus 5-fluorouracil for treatment of adenocarcinoma of the pancreas.
    Loehrer PJ; Williams SD; Nichols CR
    Cancer Treat Rep; 1987 Nov; 71(11):1115-6. PubMed ID: 3119208
    [No Abstract]   [Full Text] [Related]  

  • 12. Erlotinib and pancreatic adenocarcinoma: uncertainty and hope.
    Zoras O; Batsis C
    Ann Surg Oncol; 2011 Dec; 18 Suppl 3():S246-7. PubMed ID: 21630121
    [No Abstract]   [Full Text] [Related]  

  • 13. Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma.
    Di Bartolomeo M; Zampino MG; Di Leo A; Bajetta E
    Eur J Cancer; 1993; 29A(8):1215-6. PubMed ID: 8518036
    [No Abstract]   [Full Text] [Related]  

  • 14. [Changes in chemotherapy for pancreatic adenocarcinoma].
    Hammel P
    Gastroenterol Clin Biol; 2002; 26(6-7):603-4. PubMed ID: 12193859
    [No Abstract]   [Full Text] [Related]  

  • 15. Perspectives in chemotherapy of pancreatic cancer.
    Klapdor R
    Eur J Surg Oncol; 1991 Apr; 17(2):153-66. PubMed ID: 1707835
    [No Abstract]   [Full Text] [Related]  

  • 16. Epirubicin plus a calmodulin inhibitor (trifluoperazine) activity in advanced pancreatic adenocarcinoma. T.T.D. Cooperative Spanish Group.
    Abad A; Masuti B; Camps C; Font A; Balañá C; Vicent JM; Sánchez JJ
    Eur J Cancer; 1994; 30A(7):1043. PubMed ID: 7946573
    [No Abstract]   [Full Text] [Related]  

  • 17. Pancreatic cancer: how can we progress?
    Casper ES
    Eur J Cancer; 1993; 29A(2):171-2. PubMed ID: 8422277
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study.
    Bukowski RM; Fleming TR; Macdonald JS; Oishi N; Taylor SA; Baker LH
    Cancer; 1993 Jan; 71(2):322-5. PubMed ID: 8422624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?
    Henry NL; Hayes DF
    J Clin Oncol; 2007 Jun; 25(18):2501-3. PubMed ID: 17577024
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic advances in pancreatic cancer: miles to go before we sleep.
    Bekaii-Saab T; Goldberg R
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.